Version May 2024
| Response assessment | RECIST guideline, version 1.1[1] |
| Target lesions | |
| CR | Disappearance of all target lesions and reduction in the short axis measurement of all pathologic lymph nodes to ≤10 mm |
| PR | ≥30 percent decrease in the sum of the longest diameter of the target lesions compared with baseline |
| PD | ≥20 percent increase of at least 5 mm in the sum of the longest diameters of the target lesions compared with the smallest sum of the longest diameter recorded OR The appearance of new lesions including those detected by FDG-PET |
| SD | Neither PR nor PD |
| Non-target lesions | |
| CR | Disappearance of all non-target lesions and normalization of tumor marker levels |
| IR, SD | Persistence of one or more non-target lesions and/or the maintenance of tumor marker levels above normal limits |
| PD | The appearance of one of more new lesions or unequivocal progression. If patient has measurable disease, an increase in the overall level, or substantial worsening in non-target lesions, such that tumor burden has increased, even if there is a SD or PR in target lesions. If no measurable disease, an increase in the overall tumor burden comparable in magnitude to the increase that would be required to declare PD in measurable disease (eg, an increase in pleural effusions from trace to large, or an increase in lymphangitic disease from localized to widespread). |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
